Novo Nordisk A/S

Novo Nordisk maintains a strong capital structure with a debt-to-equity ratio of 0.27, indicating a relatively low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.7, suggesting potential short-term liquidity constraints. Free cash flow is negative at -9.25 billion DKK, driven by capital expenditures of -9.01 billion DKK, which may signal ongoing investment in growth initiatives.

Profitability metrics highlight Novo Nordisk's strong performance, with a return on equity of 25.69% and a return on assets of 8.5%. These figures exceed typical industry benchmarks for pharmaceutical firms, reflecting efficient asset utilization and strong earnings generation. The company's operating margin of 48.7% (calculated from operating income of 31.85 billion DKK on revenue of 65.35 billion DKK) further underscores its competitive position.

Geographically, Novo Nordisk's revenue is distributed across multiple regions, with no single market accounting for more than 30% of total revenue. This diversification reduces exposure to regional economic volatility and supports stable revenue streams. The company's product portfolio is similarly diversified, with a focus on diabetes care and obesity management, two high-growth therapeutic areas.

Looking ahead, Novo Nordisk is projected to maintain robust revenue growth, with current FY revenue at 65.35 billion DKK and next FY expected to show a positive delta. The company's strong R&D pipeline and market leadership in key therapeutic areas position it to capitalize on long-term industry trends. However, the negative free cash flow and capital expenditures suggest that growth is being funded through operational cash flow rather than external financing.

Risk factors for Novo Nordisk include medium liquidity risk due to a current ratio below 1 and a negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. Regulatory and geopolitical risks are moderate, with the company's global operations exposed to potential changes in healthcare policy and trade regulations.

Recent events, including analyst estimates and price targets, indicate strong investor confidence in Novo Nordisk. The mean price target of 315.90 DKK and a median of 302.50 DKK suggest a positive outlook, supported by a mean recommendation of 2.70 (leaning toward buy). The company's strong earnings and market position continue to attract institutional attention, with 4 strong-buy and 5 buy ratings.

Novo Nordisk A/S (NOVOB.CO) has experienced significant volatility in its institutional ownership structure, marked by major holder changes detected in late June 2026. Two specific investors, identified by IDs 931 and 587, executed substantial modifications to their positions as of March 31, 2026. These shifts represent the most material recent activity for the ticker, which is currently undergoing its first analysis with no prior basis for delta computation. Investor 931 demonstrated erratic positioning, initially reducing their stake from 428,743 shares (valued at $15.45 million) to just 4,027 shares (valued at $0.15 million). However, this reduction was subsequently reversed, with the investor restoring their holding to the original 428,743 shares. This back-and-forth activity, detected on June 21 and June 23, 2026, suggests a period of intense rebalancing or data correction regarding this specific holder's weight, which fluctuated between 0.0074% and a negligible 0.00007%. Simultaneously, Investor 587 underwent a dramatic increase in exposure, expanding their position from 18,861 shares (valued at $0.69 million) to 404,700 shares (valued at $14.87 million). This acquisition raised their portfolio weight from 0.0004% to 0.86%. Like Investor 931, this position was later adjusted back down to the initial 18,861 shares, indicating a similar pattern of major modification and reversal within the same reporting period. These ownership fluctuations occur within a company profiled by 10 analysts and tracked by 32 top holders, though it currently holds no index memberships. The absence of cross-source signals or material changes in fundamentals suggests that these movements are isolated to shareholder registry updates rather than broader corporate events. The significance lies in the magnitude of the share transfers, which temporarily altered the capitalization structure by tens of millions of dollars before reverting, highlighting the dynamic nature of institutional interest in Novo Nordisk.

Revenue grew at a 21.7% CAGR over four years, demonstrating strong top-line expansion momentum.

Net income CAGR of 21.0% over four years confirms robust bottom-line growth alongside revenue expansion.

Operating income declined 0.5% year-over-year in FY0, signaling a potential peak in operating profitability.

Cash conversion of 0.56 is below the 1.0 pharmaceutical cohort median, indicating weaker cash generation efficiency.

Revenue kr 79.14B, −7,6% YoY; Operating income −13,6% YoY.

• ▍Revenue kr 79.14B, −7,6% YoY
• ▍Operating income −13,6% YoY
• ▍Net income −4,7% YoY
• ▍Free cash flow −158,1% YoY
• ▍Net margin 34.0%

Revenue kr 74.98B, +5,1% YoY; Operating income −30,0% YoY.

• ▍Revenue kr 74.98B, +5,1% YoY
• ▍Operating income −30,0% YoY
• ▍Net income −26,7% YoY
• ▍Free cash flow −519,2% YoY
• ▍Net margin 26.7%

Revenue kr 76.86B, +12,9% YoY; Operating income +29,0% YoY.

• ▍Revenue kr 76.86B, +12,9% YoY
• ▍Operating income +29,0% YoY
• ▍Net income +32,2% YoY
• ▍Free cash flow +46,6% YoY
• ▍Net margin 34.5%

Revenue kr 78.09B, +19,5% YoY; Operating income +21,8% YoY.

• ▍Revenue kr 78.09B, +19,5% YoY
• ▍Operating income +21,8% YoY
• ▍Net income +14,3% YoY
• ▍Free cash flow −83,9% YoY
• ▍Net margin 37.2%

Revenue kr 85.68B; Operating income kr 36.74B.

• ▍Revenue kr 85.68B
• ▍Operating income kr 36.74B
• ▍Net margin 32.9%

Revenue kr 71.31B; Operating income kr 33.82B.

• ▍Revenue kr 71.31B
• ▍Operating income kr 33.82B
• ▍Net margin 38.3%

Revenue kr 68.06B; Operating income kr 25.93B.

• ▍Revenue kr 68.06B
• ▍Operating income kr 25.93B
• ▍Net margin 29.5%

Revenue kr 65.35B; Operating income kr 31.85B.

• ▍Revenue kr 65.35B
• ▍Operating income kr 31.85B
• ▍Net margin 38.9%

Revenue kr 309.06B, +6,4% YoY; Operating income −0,5% YoY.

• ▍Revenue kr 309.06B, +6,4% YoY
• ▍Operating income −0,5% YoY
• ▍Net income +1,4% YoY
• ▍Free cash flow −275,9% YoY
• ▍Net margin 33.1%

Revenue kr 290.40B, +25,0% YoY; Operating income +25,1% YoY.

• ▍Revenue kr 290.40B, +25,0% YoY
• ▍Operating income +25,1% YoY
• ▍Net income +20,7% YoY
• ▍Free cash flow −30,6% YoY
• ▍Net margin 34.8%

Revenue kr 232.26B, +31,3% YoY; Operating income +37,1% YoY.

• ▍Revenue kr 232.26B, +31,3% YoY
• ▍Operating income +37,1% YoY
• ▍Net income +50,7% YoY
• ▍Free cash flow −7,8% YoY
• ▍Net margin 36.0%

Revenue kr 176.95B, +25,7% YoY; Operating income +27,6% YoY.

• ▍Revenue kr 176.95B, +25,7% YoY
• ▍Operating income +27,6% YoY
• ▍Net income +16,3% YoY
• ▍Free cash flow −8,9% YoY
• ▍Net margin 31.4%